TaiMed Biologics
中裕新藥股份有限公司
TaiMed Biologics is a Taiwan TPEx-listed biotechnology company; its most advanced asset is TMB-355 / Trogarzo (FDA approved, Multidrug-resistant HIV-1 in heavily treatment-experienced adults failing their regimen), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| TMB-355 / Trogarzo | — | FDA approved | Multidrug-resistant HIV-1 in heavily treatment-experienced adults failing their regimen | United States | 2026-07-06 | Company disclosure |
| TMB-365／TMB-380 | — | Phase 2; active not recruiting | HIV -1 Infection | United States | 2026-08-06 | Trial registry |
| TMB-365 | — | Phase 1; completed | HIV-1-infection | Puerto Rico, United States | 2021-10-06 | Trial registry |
Key events
- Trogarzo received TFDA license collection notice (company disclosure)
- TMB-365/380 Phase 2b last participant enrolled (company disclosure)
Related Drugnews articles
No related articles in this language.